Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MCRPC (metastatic Castration-resistant Prostate Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05547061
What this trial is testing

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Who this might be right for
Prostate CancermCRPC
Cellbion Co., Ltd. 91
Large-scale testing (Phase 3)Study completedNCT04676334
What this trial is testing

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

Who this might be right for
Metastatic Castration-Resistant Prostate CancerOvarian CancerEpithelial Ovarian Cancer+3 more
pharmaand GmbH 34
Testing effectiveness (Phase 2)Ended earlyNCT01681433
What this trial is testing

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Who this might be right for
Prostate CancerMetastatic Castrate-Resistant Prostate CancerPSA
Costantine Albany 72
Testing effectiveness (Phase 2)Study completedNCT02711956
What this trial is testing

ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics 75
Early research (Phase 1)Ended earlyNCT04634344
What this trial is testing

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Dizal Pharmaceuticals 16
Not applicableUnknownNCT05188911
What this trial is testing

Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial

Who this might be right for
Prostate CancerCastration-resistant Prostate CancerMetastatic Disease
Fudan University 30
Testing effectiveness (Phase 2)Study completedNCT01695044
What this trial is testing

PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Progenics Pharmaceuticals, Inc. 119
Testing effectiveness (Phase 2)Study completedNCT03570619
What this trial is testing

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Who this might be right for
Metastatic Castration Resistant Prostate CancerMetastatic CancerSolid Tumor
University of Michigan Rogel Cancer Center 56
Early research (Phase 1)Study completedNCT04521361
What this trial is testing

Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

Who this might be right for
Bone Metastatic Castration-resistant Prostate Cancer
Bayer 46
Testing effectiveness (Phase 2)Looking for participantsNCT07441889
What this trial is testing

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Who this might be right for
Breast CancerProstate Cancer
University of Virginia 23
Early research (Phase 1)Looking for participantsNCT04729114
What this trial is testing

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration Resistant Prostate CancerMetastatic Castration-sensitive Prostate Cancer
Astellas Pharma Global Development, Inc. 174
Early research (Phase 1)Study completedNCT04397276
What this trial is testing

JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Who this might be right for
Neoplasms
Janssen Research & Development, LLC 82
Testing effectiveness (Phase 2)Active Not RecruitingNCT06909825
What this trial is testing

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Fusion Pharmaceuticals Inc. 85
Large-scale testing (Phase 3)Looking for participantsNCT06780670
What this trial is testing

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 443
Not applicableUnknownNCT02787837
What this trial is testing

PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate.

Who this might be right for
Advanced Prostate CancerAbiraterone ACetate
Centro Nacional de Investigaciones Oncologicas CARLOS III 220
Not applicableUnknownNCT02925702
What this trial is testing

PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.

Who this might be right for
Advanced Prostate CancerCastration ResistantRadium 223
Centro Nacional de Investigaciones Oncologicas CARLOS III 161
Testing effectiveness (Phase 2)Study completedNCT06056791
What this trial is testing

Study of INKmune in Patients With mCRPC (CaRe Prostate)

Who this might be right for
CancerMetastatic Castration-resistant Prostate CancermCRPC
Inmune Bio, Inc. 12
Large-scale testing (Phase 3)Looking for participantsNCT06136650
What this trial is testing

Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,314
Testing effectiveness (Phase 2)Ended earlyNCT04102124
What this trial is testing

SHR3680 in Combination With SHR3162 in the Treatment of mCRPC

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 20
Large-scale testing (Phase 3)Active Not RecruitingNCT06764485
What this trial is testing

Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Celgene 960
Next Page